3-氮杂双环[3.2.1]辛烷-8-酮(9ci) | 240401-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 3-氮杂双环[3.2.1]辛烷-8-酮(9ci)
• 中文别名: 3-氮杂双环[3.2.1]辛-8-酮
• 英文名称: 3-azabicyclo[3.2.1]octan-8-one
• 英文别名: 8-oxo-3-aza-bicyclo[3.2.1]octane
• CAS: 240401-35-8
• 化学式: C₇H₁₁NO
• mdl: MFCD18817585
• 分子量: 125.17
• InChiKey: LKWRGVRWBYLOFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-氮杂双环[3.2.1]辛烷-8-酮(9ci) 在 4-二甲氨基吡啶 、 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 6.5h， 生成 methyl 8-hydroxy-8-(m-tolylethynyl)-3-azabicyclo[3.2.1]octane-3-carboxylate
  参考文献：
  名称：

  Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and L-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis' AFQ-056 (Mavoglurant), which served us as a template for a scaffold hopping approach, generating a structurally diverse set of potent analogs. Both the limited aqueous solubility and the relatively poor metabolic stability of AFQ-056 were improved with hexahydrocyclopenta[c]pyrrole derivative 54a, which proved to be a valuable candidate for further development. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.059
• 作为产物：
  描述：

  3-苄基-3-氮杂双环[3.2.1]辛-8-酮 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 以74%的产率得到3-氮杂双环[3.2.1]辛烷-8-酮(9ci)
  参考文献：
  名称：

  Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and L-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis' AFQ-056 (Mavoglurant), which served us as a template for a scaffold hopping approach, generating a structurally diverse set of potent analogs. Both the limited aqueous solubility and the relatively poor metabolic stability of AFQ-056 were improved with hexahydrocyclopenta[c]pyrrole derivative 54a, which proved to be a valuable candidate for further development. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.059

文献信息

• HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160024059A1

  公开（公告）日：2016-01-28

  The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及具有以下式I的化合物及其药学上可接受的盐，其中R1、R2、R3、R5、R6、R7、R8、R9、B、V、W、X、Y、Z和m如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• Novel isoxazoline fibrinogen receptor antagonists
  申请人：——

  公开号：US20020082253A1

  公开（公告）日：2002-06-27

  Fibrinogen receptor antagonists of the formula: 1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

  式中的纤维蛋白原受体拮抗剂： 1 公开了用于抑制纤维蛋白原与血小板结合和抑制血小板聚集的纤维蛋白原受体拮抗剂。
• [EN] ARGININE METHYLTRANSFERASE INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF<br/>[FR] INHIBITEUR D'ARGININE MÉTHYLTRANSFÉRASE, COMPOSITION PHARMACEUTIQUE DE CELUI-CI ET SON UTILISATION<br/>[ZH] 一类精氨酸甲基转移酶抑制剂及其药物组合物和用途
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2019196720A1

  公开（公告）日：2019-10-17

  公开了一类精氨酸甲基转移酶抑制剂及其药物组合物和用途。具体而言，公开了具有通式(I)所示的化合物、其药学上可以接受的盐、异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物、其药物组合物和在制备用于PRMT4抑制剂或在制备治疗癌症、炎症疾病、自身免疫性疾病或糖尿病的药物中的用途。
• Design, synthesis and anti-HBV activity of NVR3-778 derivatives
  作者：Kai Lv、Shuo Wu、Wenyan Li、Yunhe Geng、Meng Wu、Jinming Zhou、Yuhuan Li、Qiang Gao、Mingliang Liu

  DOI：10.1016/j.bioorg.2019.103363

  日期：2020.1

  NVR3-778, one of the most advanced capsid assembly modulators (CAMs), is currently in phase II clinical trial for the treatment of HBV infection. In this study, we reported the first structure optimization of NVR3-778. Compound 2d was found to exhibit more potent anti-HBV activity (IC50: 0.25 mu M), lower cytotoxicity (CC50: 10.68 mu M) and higher selectivity index (SI: 40.72) than NVR3-778 (IC50: 0.33 mu M; CC50: 5.14 mu M; SI: 18.36) in vitro, and also display similar inhibitory effect on the assembly of HBV capsids as NVR3-778. Molecular docking further suggested that compound 2d might form a stronger interaction with core protein. Moreover, compound 2d also showed acceptable pharmacokinetic profiles. Currently compound 2d was selected as a new lead for further modifications, and studies to determine the in vivo anti-HBV studies of 2d will begin soon.
• US6303609B1
  申请人：——

  公开号：US6303609B1

  公开（公告）日：2001-10-16